Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418219275> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2418219275 endingPage "208" @default.
- W2418219275 startingPage "207" @default.
- W2418219275 abstract "Objectives: Gynecologic Oncology Group (GOG) 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) after primary cytoreductive surgery. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free (PFS) and overall survival (OS). Methods: Among the 550 patients enrolled in GOG 152, 216 were randomly assigned after 3 cycles of cisplatin and paclitaxel to receive SCS. In 15 patients (7%), surgery was declined or contraindicated. In the remaining 201 patients, the operative and pathology reports were used to classify their disease status at the beginning of SCS as no gross disease/microscopically negative (n = 40; 18.5%), no gross disease/microscopically positive (n = 8; 3.7%), and gross disease (n = 153; 70.8%). Results: The median PFS was 16.1 months for patients with no gross disease/microscopically negative, 13.5 months for those with no gross disease/microscopically positive, and 11.5 months for those with gross disease (P = .006). The median OS was 51.5 months for patients with no gross disease/microscopically negative, 42.6 months for those with no gross disease/microscopically positive, and 30.8 months for those with gross disease (P = .008). (See Fig. 1.) Conclusions: Although, as previously reported, SCS did not change PFS or OS, operative and pathologic findings in those who underwent the procedure were predictive of PFS and OS. Surgical/pathological residual disease is a biomarker of response to chemotherapy and predictive of PFS and OS." @default.
- W2418219275 created "2016-06-24" @default.
- W2418219275 creator A5003299608 @default.
- W2418219275 creator A5005158885 @default.
- W2418219275 creator A5005911289 @default.
- W2418219275 creator A5012623536 @default.
- W2418219275 creator A5022001569 @default.
- W2418219275 creator A5029482901 @default.
- W2418219275 creator A5059622280 @default.
- W2418219275 creator A5062151371 @default.
- W2418219275 creator A5063180871 @default.
- W2418219275 creator A5078818153 @default.
- W2418219275 creator A5088745795 @default.
- W2418219275 date "2016-06-01" @default.
- W2418219275 modified "2023-09-29" @default.
- W2418219275 title "Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study" @default.
- W2418219275 doi "https://doi.org/10.1016/j.ygyno.2016.04.534" @default.
- W2418219275 hasPublicationYear "2016" @default.
- W2418219275 type Work @default.
- W2418219275 sameAs 2418219275 @default.
- W2418219275 citedByCount "0" @default.
- W2418219275 crossrefType "journal-article" @default.
- W2418219275 hasAuthorship W2418219275A5003299608 @default.
- W2418219275 hasAuthorship W2418219275A5005158885 @default.
- W2418219275 hasAuthorship W2418219275A5005911289 @default.
- W2418219275 hasAuthorship W2418219275A5012623536 @default.
- W2418219275 hasAuthorship W2418219275A5022001569 @default.
- W2418219275 hasAuthorship W2418219275A5029482901 @default.
- W2418219275 hasAuthorship W2418219275A5059622280 @default.
- W2418219275 hasAuthorship W2418219275A5062151371 @default.
- W2418219275 hasAuthorship W2418219275A5063180871 @default.
- W2418219275 hasAuthorship W2418219275A5078818153 @default.
- W2418219275 hasAuthorship W2418219275A5088745795 @default.
- W2418219275 hasBestOaLocation W24182192751 @default.
- W2418219275 hasConcept C126322002 @default.
- W2418219275 hasConcept C141071460 @default.
- W2418219275 hasConcept C143998085 @default.
- W2418219275 hasConcept C207886595 @default.
- W2418219275 hasConcept C2779134260 @default.
- W2418219275 hasConcept C2780435969 @default.
- W2418219275 hasConcept C71924100 @default.
- W2418219275 hasConceptScore W2418219275C126322002 @default.
- W2418219275 hasConceptScore W2418219275C141071460 @default.
- W2418219275 hasConceptScore W2418219275C143998085 @default.
- W2418219275 hasConceptScore W2418219275C207886595 @default.
- W2418219275 hasConceptScore W2418219275C2779134260 @default.
- W2418219275 hasConceptScore W2418219275C2780435969 @default.
- W2418219275 hasConceptScore W2418219275C71924100 @default.
- W2418219275 hasLocation W24182192751 @default.
- W2418219275 hasOpenAccess W2418219275 @default.
- W2418219275 hasPrimaryLocation W24182192751 @default.
- W2418219275 hasRelatedWork W2002120878 @default.
- W2418219275 hasRelatedWork W2003938723 @default.
- W2418219275 hasRelatedWork W2047967234 @default.
- W2418219275 hasRelatedWork W2118496982 @default.
- W2418219275 hasRelatedWork W2364998975 @default.
- W2418219275 hasRelatedWork W2439875401 @default.
- W2418219275 hasRelatedWork W4235914821 @default.
- W2418219275 hasRelatedWork W4238867864 @default.
- W2418219275 hasRelatedWork W2519357708 @default.
- W2418219275 hasRelatedWork W2525756941 @default.
- W2418219275 hasVolume "141" @default.
- W2418219275 isParatext "false" @default.
- W2418219275 isRetracted "false" @default.
- W2418219275 magId "2418219275" @default.
- W2418219275 workType "article" @default.